Erenumab
- Generic Name
- Erenumab
- Brand Names
- Aimovig
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1582205-90-0
- Unique Ingredient Identifier
- I5I8VB78VT
- Background
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specificall...
- Indication
Erenumab is indicated for the preventative treatment of migraine in adults .
- Associated Conditions
- Migraine
- Associated Therapies
- -
Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- United States Naval Medical Center, Portsmouth
- Target Recruit Count
- 5
- Registration Number
- NCT06411067
- Locations
- 🇺🇸
Naval Medical Center Portsmouth, Portsmouth, Virginia, United States
Migraine Medication Effects on Urinary Symptoms
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT06212661
- Locations
- 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States
Aimovig Pregnancy Exposure Registry
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2842
- Registration Number
- NCT06150781
- Locations
- 🇺🇸
IQVIA Virtual Site, Durham, North Carolina, United States
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05684692
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Real World Effectiveness of Eptinezumab in Participants With Migraine
- Conditions
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- H. Lundbeck A/S
- Target Recruit Count
- 32
- Registration Number
- NCT05284019
- Locations
- 🇺🇸
Gilbert Neurology Partners/ CCT Research, Gilbert, Arizona, United States
🇺🇸Ki Clinical Research LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸Innovation Medical Group, Palmetto Bay, Florida, United States
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Austrian Migraine Registry Collaboration
- Target Recruit Count
- 1500
- Registration Number
- NCT05281770
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Tirol, Austria
🇦🇹Clinic Hietzing, Vienna, Austria
🇦🇹Medizinische Universität Wien, Wien, Vienna, Austria
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 5
- Registration Number
- NCT05142228
- Locations
- 🇺🇸
University of Maryland, School of Dentistry, Brotman Facial Pain Clinic, Baltimore, Maryland, United States
Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19
- Conditions
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Fayoum University
- Target Recruit Count
- 90
- Registration Number
- NCT05052008
- Locations
- 🇪🇬
Marwa Kamal Ahmed Tolba, Fayoum, Egypt
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT04825678
- Locations
- 🇺🇸
Asheville Neurology Specialists PA, Asheville, North Carolina, United States
🇺🇸New Age Medical Research Corporation, Miami, Florida, United States
🇺🇸Mountain Neurological Research Center, Basalt, Colorado, United States
Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 250
- Registration Number
- NCT04674020
- Locations
- 🇩🇰
Danish Headache Center, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.